Newsfile Corp
17 Jul 2026, 23:50 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
2 claims · each scored for market impact
Grail's NHS-Galleri Trial failed to observe a statistically significant reduction in Stage III-IV cancers, leading to a stock price drop of over 50% on February 19, 2026. — The failure of a primary endpoint in a major clinical trial for a core product is a fundamental blow to the company's value proposition and growth prospects.
-0.90A class action lawsuit has been filed against Grail alleging that management made false or misleading statements regarding the probability of achieving the NHS-Galleri trial's primary endpoint. — Securities fraud litigation creates significant legal overhang, potential for large settlements, and damages management credibility.
-0.40Which stocks this story touches
The company is facing a class action lawsuit following a 50% stock price drop and failure to meet a primary trial endpoint.
Continue reading
6 related stories
Search tags
The company is mentioned as the subject of an investor class action lawsuit due to substantial losses.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Newsfile Corp
4h ago
